Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression

Molecular and Cellular Proteomics

Volumn 12, Issue 6, 2013, Pages 1589-1601

  Saraon, Punit ^a,b   Cretu, Daniela ^a,b   Musrap, Natasha ^a,b   Karagiannis, George S ^a,b   Batruch, Ihor ^a   Drabovich, Andrei P ^a   Van Der Kwast, Theodorus ^b,c   Mizokami, Atsushi ^d   Morrissey, Colm ^e   Jarvi, Keith ^a   Diamandis, Eleftherios P ^a,b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; ACAT1 PROTEIN; BDH1 PROTEIN; HMGCL PROTEIN; HMGCS2 PROTEIN; OXCT1 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DOWN REGULATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KETOGENESIS; MALE; MASS SPECTROMETRY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEOMICS; UPREGULATION; WESTERN BLOTTING;

ACETYL-COA C-ACETYLTRANSFERASE; CELL LINE, TUMOR; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA SYNTHASE; ISOTOPE LABELING; MALE; MASS SPECTROMETRY; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PROSTATE; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878680914     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.M112.023887     Document Type: Article

References (61)

1. Gronberg, H. (2003) Prostate cancer epidemiology. Lancet 361, 859-864 (Pubitemid 36331852)
2. Javidan, J., Deitch, A. D., Shi, X. B., and de Vere White, R. W. (2005) The androgen receptor and mechanisms for androgen independence in prostate cancer. Cancer Invest. 23, 520-528 (Pubitemid 41463868)
3. Saraon, P., Jarvi, K., and Diamandis, E. P. (2011) Molecular alterations during progression of prostate cancer to androgen independence. Clin. Chem. 57, 1366-1375
4. Denmeade, S. R., and Isaacs, J. T. (2002) A history of prostate cancer treatment. Nat. Rev. Cancer 2, 389-396 (Pubitemid 37328952)
5. Crawford, E. D., and Petrylak, D. (2010) Castration-resistant prostate cancer: descriptive yet pejorative? J. Clin. Oncol. 28, e408
6. Chodak, G. W., Kranc, D. M., Puy, L. A., Takeda, H., Johnson, K., and Chang, C. (1992) Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. J. Urol. 147, 798-803
7. Ruizeveld de Winter, J. A., Trapman, J., Vermey, M., Mulder, E., Zegers, N. D., and van der Kwast, T. H. (1991) Androgen receptor expression in human tissues: an immunohistochemical study. J. Histochem. Cytochem. 39, 927-936
8. Sadi, M. V., Walsh, P. C., and Barrack, E. R. (1991) Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer 67, 3057-3064
9. Debes, J. D., and Tindall, D. J. (2004) Mechanisms of androgen-refractory prostate cancer. N. Engl. J. Med. 351, 1488-1490 (Pubitemid 39315314)
10. Edwards, J., and Bartlett, J. M. (2005) The androgen receptor and signaltransduction pathways in hormone-refractory prostate cancer. Part 2: androgen-receptor cofactors and bypass pathways. BJU Int. 95, 1327-1335 (Pubitemid 40799455)
11. Wilding, G., Chen, M., and Gelmann, E. P. (1989) Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 14, 103-115 (Pubitemid 19154802)
12. Iwasa, Y., Mizokami, A., Miwa, S., Koshida, K., and Namiki, M. (2007) Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP. Int. J. Urol. 14, 233-239 (Pubitemid 46423241)
13. Wu, T. T., Sikes, R. A., Cui, Q., Thalmann, G .N., Kao, C., Murphy, C. F., Yang, H., Zhau, H. E., Balian, G., Chung, L. W. (1998) Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int. J. Cancer 77, 887-894 (Pubitemid 28378138)
14. Thalmann, G. N., Sikes, R. A., Wu, T. T., Degeorges, A., Chang, S. M., Ozen, M., Pathak, S., Chung, L. W. (2000) LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate 44, 91-103 (Pubitemid 30419183)
15. Igawa, T., Lin, F. F., Lee, M. S., Karan, D., Batra, S. K., and Lin, M. F. (2002) Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate 50, 222-235 (Pubitemid 34184661)
16. Zhou, J. R., Yu, L., Zerbini, L. F., Libermann, T. A., and Blackburn, G. L. (2004) Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations. Int. J. Cancer 110, 800-806 (Pubitemid 38758504)
17. Shi, X. B., Ma, A. H., Tepper, C. G., Xia, L., Gregg, J. P., Gandour-Edwards, R., Mack, P. C., Kung, H. J., deVere White, R. W. (2004) Molecular alterations associated with LNCaP cell progression to androgen independence. Prostate 60, 257-271 (Pubitemid 38971837)
18. Konig, J. J., Teubel, W., van Steenbrugge, G. J., Romijn, J. C., and Hagemeijer, A. (1999) Characterization of chromosome 8 aberrations in the prostate cancer cell line LNCaP-FGC and sublines. Urol. Res. 27, 3-8 (Pubitemid 29145084)
19. Tyson, D. R., and Ornstein, D. K. (2008) Proteomics of cancer of hormonedependent tissues. Adv. Exp. Med. Biol. 630, 133-147
20. Zheng, Y., Xu, Y., Ye, B., Lei, J., Weinstein, M. H., O'Leary, M. P., Richie, J. P., Mok, S. C., Liu, B. C. (2003) Prostate carcinoma tissue proteomics for biomarker discovery. Cancer 98, 2576-2582 (Pubitemid 37509520)
21. Sardana, G., Jung, K., Stephan, C. and Diamandis, E. P. (2008) Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J. Proteome Res. 7, 3329-3338
22. Alaiya, A. A., Al-Mohanna, M., Aslam, M., Shinwari, Z., Al-Mansouri, L., Al-Rodayan, M., Al-Eid, M., Ahmad, I., Hanash, K., Tulbah, A., Bin Mahfooz, A., Adra, C. (2011) Proteomics-based signature for human benign prostate hyperplasia and prostate adenocarcinoma. Int. J. Oncol. 38, 1047-1057
23. Skvortsov, S., Schäfer, G., Stasyk, T., Fuchsberger, C., Bonn, G. K., Bartsch, G., Klocker, H., Huber, L. A. (2011) Proteomics profiling of microdissected low- and high-grade prostate tumors identifies Lamin A as a discriminatory biomarker. J. Proteome Res. 10, 259-268
24. Saraon, P., Musrap, N., Cretu, D., Karagiannis, G. S., Batruch, I., Smith, C., Drabovich, A. P., Trudel, D., van der Kwast, T., Morrissey, C., Jarvi, K. A., Diamandis, E. P. (2012) Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castrate-resistant prostate cancer. J. Biol. Chem. 287, 34019-34031
25. Khan, A. P., Poisson, L. M., Bhat, V. B., Fermin, D., Zhao, R., Kalyana- Sundaram, S., Michailidis, G., Nesvizhskii, A. I., Omenn, G. S., Chinnaiyan, A. M., Sreekumar, A. (2010) Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer. Mol. Cell. Proteomics 9, 298-312
26. Diamandis, E. P. (1998) Prostate-specific antigen: its usefulness in clinical medicine. Trends Endocrinol. Metab. 9, 310-316 (Pubitemid 28471340)
27. Sauter, E. R., Scott, S., Hewett, J., Kliethermes, B., Ruhlen, R. L., Basarakodu, K., de la Torre, R. (2008) Biomarkers associated with breast cancer are associated with obesity. Cancer Detect. Prev. 32, 149-155
28. Montgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., Nelson, P. S. (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 68, 4447-4454
29. Maresh, E. L., Mah, V., Alavi, M., Horvath, S., Bagryanova, L., Liebeskind, E. S., Knutzen, L. A., Zhou, Y., Chia, D., Liu, A. Y., Goodglick, L. (2010) Differential expression of anterior gradient gene AGR2 in prostate cancer. BMC Cancer 10, 680
30. Touma, S. E., Perner, S., Rubin, M. A., Nanus, D. M., and Gudas, L. J. (2009) Retinoid metabolism and ALDH1A2 (RALDH2) expression are altered in the transgenic adenocarcinoma mouse prostate model. Biochem. Pharmacol. 78, 1127-1138
31. Basu, G. D., Azorsa, D. O., Kiefer, J. A., Rojas, A. M., Tuzmen, S., Barrett, M. T., Trent, J. M., Kallioniemi, O., Mousses, S. (2008) Functional evidence implicating S100P in prostate cancer progression. Int. J. Cancer 123, 330-339 (Pubitemid 351842017)
32. Flamand, V., Zhao, H., and Peehl, D. M. (2010) Targeting monoamine oxidase A in advanced prostate cancer. J. Cancer Res. Clin. Oncol. 136, 1761-1771
33. Chang, J. W., Nomura, D. K., and Cravatt, B. F. (2011) A potent and selective inhibitor of KIAA1363/AADACL1 that impairs prostate cancer pathogenesis. Chem. Biol. 18, 476-484
34. Quirós, I., Sáinz, R. M., Hevia, D., García- Suárez, O., Astudillo, A., Rivas, M., Mayo, J. C. (2009) Upregulation of manganese superoxide dismutase (SOD2) is a common pathway for neuroendocrine differentiation in prostate cancer cells. Int. J. Cancer 125, 1497-1504
35. Degraff, D. J., Aguiar, A. A., and Sikes, R. A. (2009) Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions. Am. J. Transl. Res. 1, 115-130
36. Chung, M. K., Kim, H. J., Lee, Y. S., Han, M. E., Yoon, S., Baek, S. Y., Kim, B. S., Kim, J. B., Oh, S. O. (2010) Hedgehog signaling regulates proliferation of prostate cancer cells via stathmin1. Clin. Exp. Med. 10, 51-57
37. Chen, M. F., Chen, W. C., Chang, Y. J., Wu, C. F., and Wu, C. T. (2010) Role of DNA methyltransferase 1 in hormone-resistant prostate cancer. J. Mol. Med. 88, 953-962
38. Zou, J. X., Guo, L., Revenko, A. S., Tepper, C. G., Gemo, A. T., Kung, H. J., Chen, H. W. (2009) Androgen-induced coactivator ANCCA mediates specific androgen receptor signaling in prostate cancer. Cancer Res. 69, 3339-3346
39. Mortezavi, A., Hermanns, T., Seifert, H. H., et al. (2011) KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin. Cancer Res. 17, 1111-1121
40. Oram, S. W., Ai, J., Pagani, G. M., Hitchens, M. R., Stern, J. A., Eggener, S., Pins, M., Xiao, W., Cai, X., Haleem, R., Jiang, F., Pochapsky, T. C., Hedstrom, L., Wang, Z. (2007) Expression and function of the human androgen-responsive gene ADI1 in prostate cancer. Neoplasia 9, 643-651 (Pubitemid 47328083)
41. Suh, J., and Rabson, A. B. (2004) NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon? J. Cell. Biochem. 91, 100-117
42. Cohen, M. B., and Rokhlin, O. W. (2009) Mechanisms of prostate cancer cell survival after inhibition of AR expression. J. Cell. Biochem. 10, 363-371
43. Balistreri, C. R., Caruso, C., Carruba, G., Miceli, V., and Candore, G. (2011) Genotyping of sex hormone-related pathways in benign and malignant human prostate tissues: data of a preliminary study. OMICS 15, 369-374
44. Wegiel, B., Evans, S., Hellsten, R., Otterbein, L. E., Bjartell, A., and Persson, J. L. (2010) Molecular pathways in the progression of hormone-independent and metastatic prostate cancer. Curr. Cancer Drug Targets 10, 392-401
45. Sankpal, U. T., Goodison, S., Abdelrahim, M., and Basha, R. (2011) Targeting sp1 transcription factors in prostate cancer therapy. J. Med. Chem. 7, 518-525
46. Puisac, B., Ramos, M., Arnedo, M., Menao, S., Gil-Rodriíguez, M. C., Teresa-Rodrigo, M. E., Pié, A., de Karam, J. C., Wesselink, J. J., Giménez, I., Ramos, F. J., Casals, N., Gómez-Puertas, P., Hegardt, F. G., Pié, J. (2011) Characterization of splice variants of the genes encoding human mitochondrial HMG-CoA lyase and HMG-CoA synthase, the main enzymes of the ketogenesis pathway. Mol. Biol. Rep. 39, 4777-85
47. Nakamura, M. T., Cheon, Y., Li, Y., and Nara, T. Y. (2004) Mechanisms of regulation of gene expression by fatty acids. J. Lipids 39, 1077-1083 (Pubitemid 40129050)
48. Massie, C. E., Lynch, A., Ramos-Montoya, A., Boren, J., Stark, R., Fazli, L., Warren, A., Scott, H., Madhu, B., Sharma, N., Bon, H., Zecchini, V., Smith, D. M., Denicola, G. M., Mathews, N., Osborne, M., Hadfield, J., Macarthur, S., Adryan, B., Lyons, S. K., Brindle, K. M., Griffiths, J., Gleave, M. E., Rennie, P. S., Neal, D. E., Mills, I. G. (2011) The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 30, 2719-2733
49. Liu, Y. (2006) Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis. 9, 230-234 (Pubitemid 44317255)
50. Benedettini, E., Nguyen, P., and Loda, M. (2008) The pathogenesis of prostate cancer: from molecular to metabolic alterations. Diagn. Histopathol. 14, 195-201 (Pubitemid 351815049)
51. Rossi, S., Graner, E., Febbo, P., Weinstein, L., Bhattacharya, N., Onody, T., Bubley, G., Balk, S., Loda, M. (2003) Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol. Cancer Res. 1, 707-715 (Pubitemid 37025589)
52. Moore, S., Knudsen, B., True, L. D., Hawley, S., Etzioni, R., Wade, C., Gifford, D., Coleman, I., Nelson, P. S. (2005) Loss of stearoyl-CoA desaturase expression is a frequent event in prostate carcinoma. Int. J. Cancer 114, 563-571 (Pubitemid 40349614)
53. Zha, S., Ferdinandusse, S., Hicks, J. L., Denis, S., Dunn, T. A., Wanders, R. J., Luo, J., De Marzo, A. M., Isaacs, W. B. (2005) Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. Prostate 63, 316-323 (Pubitemid 40664342)
54. Luo, J., Zha, S., Gage, W. R., Dunn, T. A., Hicks, J. L., Bennett, C. J., Ewing, C. M., Platz, E. A., Ferdinandusse, S., Wanders, R. J., Trent, J. M., Isaacs, W. B., De Marzo, A. M. (2002) Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 62, 2220-2226 (Pubitemid 34411693)
55. Kumar-Sinha, C., Shah, R. B., Laxman, B., Tomlins, S. A., Harwood, J., Schmitz, W., Conzelmann, E., Sanda, M. G., Wei, J. T., Rubin, M. A., Chinnaiyan, A. M. (2004) Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer. Am. J. Path. 164, 787-793 (Pubitemid 38235461)
56. Locke, J. A., Wasan, K. M., Nelson, C. C., Guns, E. S., and Leon, C. G. (2008) Androgen-mediated cholesterol metabolism in LNCaP and PC-3 cell lines is regulated through two different isoforms of acyl-coenzyme A:cholesterol acyltransferase (ACAT). Prostate 68, 20-33
57. Leon, C. G., Locke, J. A., Adomat, H. H., Etinger, S. L., Twiddy, A. L., Neumann, R. D., Nelson, C. C., Guns, E. S., Wasan, K. M. (2010) Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate 70, 390-400
58. Leon, C., Hill, J. S., and Wasan, K. M. (2005) Potential role of acylcoenzyme A:cholesterol transferase (ACAT) inhibitors as hypolipidemic and antiatherosclerosis drugs. Pharm. Res. 22, 1578-1588 (Pubitemid 41355897)
59. Yoshinaka, Y., Shibata, H., Kobayashi, H., Kuriyama, H., Shibuya, K., Tanabe, S., Watanabe, T., Miyazaki, A. (2010) A selective ACAT-1 inhibitor, K-604, stimulates collagen production in cultured smooth muscle cells and alters plaque phenotype in apolipoprotein E-knockout mice. Atherosclerosis 213, 85-91
60. McKnight, S. L. (2010) On getting there from here. Science 330, 1338-1339
61. Canacci, A. M., Izumi, K., Zheng, Y., Gordetsky, J., Yao, J. L., Miyamoto, H. (2011) Expression of semenogelins I and II and its prognostic significance in human prostate cancer. Prostate 71, 1108-1114